ABSTRACT Antibiotic aerosol treatment is successful in treating Pseudomonas infection in some patients with cystic fibrosis, but the amount of drug reaching the lungs is unknown. The deposition patterns of carbenicillin aerosols delivered from two commercially available nebuliser systems (the Turret nebuliser plus Maxi compressor and the Inspiron nebuliser plus Traveller compressor) have been compared in six patients with cystic fibrosis during tidal breathing. The aerosol mass median diameters were 3-2 and 7-3 um. In addition, the aerosol from the Turret-Maxi nebuliser system was inhaled by a combination of tidal and deep breathing. After two minutes' breathing via a mouthpiece the mean (SEM) deposition in the lungs was 15-60 (1 -5) 
breathing.produced a further small but non-significant increase in lung aerosol deposition. A seventh patient, who failed to complete the trial, had little aerosol deposited in his lungs because he inhaled through his nose. These results emphasise the importance of correct selection of nebuliser equipment for antibiotic aerosol treatment.
Antibiotic aerosol treatment originated in the 1940s, when various antibiotics were inhaled either as nebulised solutions' 2 or as dry powders' to treat respiratory tract infections. Although this practice waned in popularity, it has recently been revived, particularly to treat Pseudomonas infection in some patients with cystic fibrosis."7 The efficacy of aerosol antibiotic treatment may depend in part on the choice of nebuliser equipment; in vitro laboratory studies have suggested that the quantities of gentamicin,8 carbenicillin,9 ceftazidime, and colistin"' reaching the lungs may vary widely according to the type of nebuliser and compressor.
Relatively little is known about the site of deposition of antibiotic aerosol within the respiratory tract, and the extent to which the aerosol penetrates to the more peripheral lung regions. In 9 The flow rates generated by the Maxi and Traveller compressors through their respective nebulisers were 9 and 6 I/min. The Inspiron nebuliser was connected to a one way valve system (Ambu-Valve, Tricomed, London), the outlet from which led to a low resistance filter (Inspiron 002290) so that no aerosol was vented into the room; the Turret nebuliser incorporated a built in valve system. Each patient used a different nebuliser to prevent cross contamination and nebulisers, valves, and tubing were sterilised after each experiment.
Radioaerosol studies were performed on three separate days in a randomised order as follows: (1) Inspiron nebuliser plus Traveller compressor with tidal breathing (7 3 pm aerosol); (2) Turret nebuliser plus Maxi compressor with tidal breathing (32 ,um aerosol; (3) Turret nebuliser plus Maxi compressor with a combination of tidal and deep breathing (3-2 pm aerosol). In the third study patients were instructed to take alternately four tidal breaths and four deep breaths of 1 -0-15 1 in volume. Inhaled volume, breathing frequency, and minute ventilation were determined by respiratory inductive plethysmography (Respitrace Corporation, Ardsley, New York) which was used to monitor the inhalation manoeuvres as described.'6 To provide a rough check on the inhaled volume while aerosol was being inhaled, the air inlet to"the nebuliser was connected to a Voldyne incentive spirometer (Cheeseborough Ponds Inc, Greenwich, Conneticut). Patients inhaled aerosol for two minutes via a mouthpiece with the body of the nebuliser shielded by a lead screen. Inhalations were preceded by 10 minutes' chest physiotherapy (forced expiration technique'7) to clear loose secretions from the lungs. Forced expiratory volume in one second (FEV,) was assessed immediately before aerosol inhalation by spirometry (Vitalograph), and maximum expiratory flow rate at 75% of the forced vital capacity (Vmax25) from an Ohio spirometer coupled to an x-y plotter.
A posterior-anterior scan of radioaerosol in the chest and stomach was performed with a General Electric 400T large field of view gamma camera, starting within 60 seconds of the end of nebulisation. Counting times were 100-200 seconds and at least 40 000 counts were collected. Aerosol located in the oropharynx was then determined from a right lateral view of the head. The gamma camera was connected on line to a Nodecrest V77 600 computer, which was used to define "regions of interest" on the scans around the lungs, stomach, and oropharynx. The chest count was corrected for the. patient's chest thickness according to the attenuation equations of Fleming. 8 Counts emanating from the stomach during scans were assumed to have arisen from aerosol initially deposited in the oropharynx and subsequently swallowed. The total amount of carbenicillin initially deposited in the lungs and oropharynx was determined by comparing the counts obtained with those from a lung "phantom" similar in design to the models described previously.'920 The phantom consisted of a 25 cm diameter hollow perspex disc 3 cm thick, filled with a known amount of the "labelled" carbenicillin (about 5 mg). The perspex disc was mounted in a wooden frame and positioned 10 cm from a 1 cm thick slab of tissue equivalent material to simulate the chest wall. The 10 cm air gap represented air in the lungs and the perspex disc activity in mid thorax. For scanning the phantom was placed in front of the gamma camera with the tissue equivalent slab in contact with the surface of the collimator.
Each patient had a krypton-81m ventilation scan, after one of the radioaerosol studies, inhaling the radioactive gas from a generator (the Medical Research Council cyclotron). The 20% contour of the 8ImKr scan was then superimposed on the aerosol images and used to define the lung edge. Radioaerosol counts in .three further lung zones (central, intermediate, and peripheral- fig 1) were determined from three "regions of interest" as described by Agnew et al.2' An aerosol penetration index was defined as the ratio of perinpheral zone counts to central zone counts, averaged for the two lungs.
The data were not assumed to be normally distributed. Statistical significance was assessed by the Wilcoxon rank sum test for paired data. reasons. The mean (SEM) amount of carbenicillin reaching the lungs in the other six patients was 6- The patient who withdrew from the study had inhaled only the 3-2 um aerosol by tidal breathing. In this case only 1-84 mg carbenicillin was deposited in Newman, Woodman, Clarke the lungs, compared with a mean of 15-6 mg in the remaining six patients. When he returned to the laboratory it was apparent that he drew aerosol into his mouth via the mouthpiece but inhaled through his nose. A repeat study was performed with the patient wearing a noseclip and the mass of carbenicillin in the lungs rose almost threefold to 4-85 mg.
LUNG FUNCTION AND INHALATION MANOEUVRES
Lung function, inhalation volumes and breathing frequencies were similar on each study day (table 1) .
With alternate tidal and deep breathing, minute ventilation increased compared to tidal breathing alone (p < 0 05).
Discussion
Deposition of carbenicillin was determined by mixing the "'Tc and drug solution within the nebulisers rather than by labelling the drug with the radionuclide chemically. Droplets released subsequently are assumed to contain drug and radiolabel in the same proportions as in the nebuliser reservoir, so that the distribution of radioaerosol in the lungs and oropharynx reflects that of the drug. The validity of this assumption has been discussed by Dashe et Deposition ofcarbenicillin aerosols in cystic fibrosis: effects ofnebuliser system and breathing pattern loss of tracer from the field of view; inhalation was restricted to two minutes to further minimise the effects of absorption of the radiotracer. The radiation dose to the lungs has been estimated as 200 pGy (20 mrad) , which is about half that from a chest radiograph.26
The deposition data indicate that the amount of antibiotic aerosol delivered to the patient's lungs may be influenced dramatically by choice of nebuliser system, as predicted from in vitro studies."' During two minutes' nebulisation more drug was delivered to the patient from the Turret nebuliser with the Maxi compressor (20 5 mg in lungs plus oropharynx) than from the Inspiron nebuliser plus Traveller compressor (16-1 mg), presumably because the Turret was driven at a higher compressed gas flow rate. With the Turret nebuliser plus Maxi compressor 76% of the aerosol reaching the patient was deposited in the lungs, compared with 41% for the Inspiron nebuliser plus thus countering the effect of inhaling deeply, and this may explain the similar aerosol distributions for the two breathing modes. Attention to inhalation technique may be important, however. The low deposition in the patient who inhaled through the nose while receiving the aerosol via a mouthpiece suggests that some patients may be using their nebulisers incorrectly and may consequently derive little therapeutic benefit.
The use of a noseclip or facemask should help to eliminate simple errors of this type, and could usefully be considered in patients who are not deriving the expected benefit from treatment. The nebuliser systems tested in this study may have represented opposite extremes so far as droplet mass median diameters are concerned; most other systems probably have an MMD in the range 3-7 pm.9 Large droplet sizes are sometimes, but not always, associated with relatively weak "portable" brands ofcompressor. Droplet MMD varies inversely with the pressure or flow rate generated by a compressor, but it also depends on the type of nebuliser. In vitro studies have 322 shown that the weaker compressors are often unsatisfactory because of the time taken to nebulise a standard dose of carbenicillin9; this study indicates that weaker compressors may also be unsatisfactory because they lead to the generation of larger aerosol droplets, fewer of which reach the lungs. A relatively powerful compressor, coupled to a nebuliser with a droplet MMD of less than 5 tm, is thus the system of choice for antibiotic aerosol treatment.
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